Linked Life Data

1801885

Source:http://linkedlifedata.com/resource/pubmed/id/1801885

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1992-4-28
pubmed:abstractText
Thirty-two patients with metastatic colorectal cancer were entered in a phase II study of ACNU as first-line treatment. ACNU was given at a dose of 100 mg/m2 i.v. every six weeks. In 30 evaluable patients we observed partial responses lasting 5 and 8 months in 2 patients with liver metastases, and stable disease in 4 patients. The toxicity mainly consisted of leuco- and trombocytopenia. We conclude that in this dose and schedule ACNU has only very limited activity in metastatic colorectal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
767-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Phase II study of ACNU as first-line treatment in advanced colorectal cancer.
pubmed:affiliation
Department of Medical Oncology, Rotterdam Cancer Center/Dr. Daniel den Hoed Kliniek, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't